NASDAQ: EUDAEuda Health Holdings Ltd Stock
$17.31-1.99 (-10.31%)
Updated Aug 3, 2026
EUDA Price
$17.31
Fair Value Price
N/A
Market Cap
$32.72M
52 Week Low
$5.26
52 Week High
$86.00
P/E
-11.7x
P/B
-7.69x
P/S
12.65x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.82M
Earnings
-$2.77M
Gross Margin
43.9%
Operating Margin
-36.69%
Profit Margin
-40.7%
Debt to Equity
-1.41
Operating Cash Flow
-$2M
Beta
-0.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EUDA Overview
8i Acquisition 2 Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets companies in Asia. 8i Acquisition 2 was incorporated in 2021 and is headquartered in Singapore.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EUDA's potential to beat the market
- EUDA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
EUDA
RankedUnranked of 42
RankedUnranked of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $37.65 | A | |
| $60.47 | A | |
| $19.50 | B |
Be the first to know about important EUDA news, forecast changes, insider trades & much more!
EUDA News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EUDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EUDA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EUDA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
EUDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more EUDA due diligence checks available for Premium users.
Valuation
EUDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.7x
Industry
9.91x
Market
14.82x
EUDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.69x
Industry
3.43x
EUDA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
EUDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EUDA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7M
Liabilities
$6.0M
Debt to equity
-1.41
EUDA's short-term liabilities ($5.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EUDA's short-term assets ($1.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EUDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EUDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
EUDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EUDA vs Health Information Service Stocks
Euda Health Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.